A novel molecule ZYZ329 targeting histone methyltransferase SMYD3 suppresses pathological angiogenesis via the driven mitochondrial ROS/HIF-1α/VEGFA axis [PDF]
Background The histone methyltransferase SMYD3 (SET and MYND domain containing 3) is critical for vascular homeostasis and may be implicated in pathological angiogenesis.
Qing Ye +8 more
doaj +2 more sources
SMYD3 synergises with RACK1 to promote colorectal cancer lung metastasis by recruiting SMAD3 [PDF]
Cancer metastasis is the leading cause of mortality associated with cancer, and the prognosis for patients diagnosed with colorectal cancer(CRC) largely depends on the occurrence of metastasis during the progression of the disease.
Xiaoming Bai +11 more
doaj +2 more sources
SMYD3 confers cisplatin chemoresistance of NSCLC cells in an ANKHD1-dependent manner
Background: Cisplatin (DDP) remains the backbone of chemotherapy for non-small cell lung cancer (NSCLC), yet its clinical efficacy is limited by DDP resistance. We aim to investigate the role of the SET and MYND domain-containing protein 3 (SMYD3) in DDP
Yin Li, Wen-Qun Xing, Yin Li
exaly +3 more sources
SMYD3–CDCP1 Axis Drives EMT and CAF Activation in Colorectal Cancer and Is Targetable for Oxaliplatin Sensitization [PDF]
Background: Colorectal cancer (CRC) mortality is predominantly driven by liver metastasis and poor responsiveness to chemotherapy. The histone methyltransferase SMYD3 has been implicated in oncogenic transcriptional programs; however, its downstream ...
Liming Zhao +5 more
doaj +2 more sources
Loss of histone methyltransferase Smyd3 triggers WAT browning and adaptive thermogenesis via enhancing PPARγ expression in a H4K20me3-dependent manner [PDF]
Adaptive thermogenesis driven by brown/beige adipose tissue has gained attention as a promising strategy for combating obesity. Histone methyltransferase SET and MYND Domain Containing 3 (Smyd3) is strongly associated with metabolic and cardiovascular ...
Meiling Shu +7 more
doaj +2 more sources
Tailoring a novel colorectal cancer stem cell-targeted therapy by inhibiting the SMYD3/c-MYC axis [PDF]
Cancer stem cells (CSCs) are responsible for colorectal cancer (CRC) chemoresistance, recurrence, and metastasis. Therefore, identifying molecular stemness targets that are involved in tumor growth is crucial for effective treatment.
Martina Lepore Signorile +27 more
doaj +2 more sources
SMYD3 drives cell cycle and epithelial-mesenchymal transition pathways through dual gene transcriptional repression and activation in HPV-negative head and neck cancer [PDF]
Human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer type in the world and is associated with an overall poor prognosis.
Madhavi Murali +10 more
doaj +2 more sources
The novel SMYD3 inhibitor EM127 impairs DNA repair response to chemotherapy-induced DNA damage and reverses cancer chemoresistance [PDF]
Background SMYD3 has been found implicated in cancer progression. Its overexpression correlates with cancer growth and invasion, especially in gastrointestinal tumors.
Paola Sanese +25 more
doaj +2 more sources
Investigating SMYD3 role during oocyte maturation in a 3D follicle-enclosed oocyte in vitro model in sheep [PDF]
BackgroundSMYD3 is a histone methyltransferase known for its dual role in modifying both histone and non-histone proteins. Despite its established involvement in somatic cell function and oncogenesis, its role in mammalian oogenesis and early embryonic ...
Chiara Camerano Spelta Rapini +10 more
doaj +2 more sources
Oncogenic activation of SMYD3-SHCBP1 promotes breast cancer development and is coupled with resistance to immune therapy [PDF]
Breast cancer initiation and progression are driven by various oncogenic factors and their effects on the surrounding microenvironments. Through integrative analysis of ChIP-sequencing and RNA-sequencing with fast proliferating mammary epithelial cells ...
Lihua Mo +18 more
doaj +2 more sources

